Zhejiang Taimei Medical Technology Co. Ltd. reported its interim financial results for the six months ended June 30, 2025. The company posted revenue of RMB244.2 million, representing a decrease of 10.5% compared to RMB272.8 million in the same period last year. Gross profit for the period was RMB100.2 million, down 9.7% from RMB110.9 million in the prior-year period. The loss for the period narrowed significantly to RMB29.3 million, compared to a loss of RMB175.3 million in the previous year, a decrease of 83.3%. The company also reported an adjusted net loss (non-IFRS measure) of RMB28.7 million, down 41.7% from RMB49.3 million in the prior-year period. Net finance income increased to RMB19.4 million from RMB16.7 million, mainly due to higher interest income. The company recorded net other losses of RMB12.9 million, compared to net gains of RMB7.8 million in the same period last year, largely driven by a swing from net foreign exchange gains to losses. As of June 30, 2025, total assets stood at RMB1.52 billion, down from RMB1.58 billion at the end of 2024. During the reporting period, Zhejiang Taimei Medical Technology Co. Ltd. did not make any significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures. The company stated it does not have plans for material investments or capital assets for the reporting period and up to the date of the report.